Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.

Ghosh S, Schuster FR, Binder V, Niehues T, Baldus SE, Seiffert P, Laws HJ, Borkhardt A, Meisel R.

J Clin Immunol. 2012 Jun;32(3):438-40. doi: 10.1007/s10875-012-9654-7. Epub 2012 Feb 23.

PMID:
22354567
2.

Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.

Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.

Biol Blood Marrow Transplant. 2010 Jun;16(6):818-23. doi: 10.1016/j.bbmt.2010.01.002. Epub 2010 Jan 14.

3.

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.

Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.

Cancer. 2002 May 1;94(9):2409-15.

4.

Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).

Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M; Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).

Pediatr Hematol Oncol. 2007 Sep;24(6):393-402.

PMID:
17710656
5.

Ataxia-telangiectasia with hyper-IgM and Wilms tumor: fatal reaction to irradiation.

Pietrucha BM, Heropolitańska-Pliszka E, Wakulińska A, Skopczyńska H, Gatti RA, Bernatowska E.

J Pediatr Hematol Oncol. 2010 Jan;32(1):e28-30. doi: 10.1097/MPH.0b013e3181bfd3d9.

PMID:
20051774
6.

[Allogeneic hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis type 1: a case report].

Ou RM, Wang L, Zheng LL, Yao MD, Jiang WT, Zhou CH.

Zhongguo Dang Dai Er Ke Za Zhi. 2006 Jun;8(3):181-3. Chinese.

PMID:
16787585
7.

Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience.

Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, Morio T, Nonoyama S, Mizutani S.

Am J Hematol. 2004 May;76(1):33-9.

9.

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C.

Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17.

PMID:
21584670
10.

Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.

Sung KW, Park JE, Chueh HW, Lee SH, Yoo KH, Koo HH, Kim JY, Cho EJ.

Pediatr Blood Cancer. 2011 Oct;57(4):660-5. doi: 10.1002/pbc.23035. Epub 2011 Jun 16.

PMID:
21681924
11.

[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].

Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M.

Dtsch Med Wochenschr. 2005 Sep 23;130(38):2125-9. German.

PMID:
16172951
12.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ.

Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56.

13.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.

Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.

Bone Marrow Transplant. 2001 Oct;28(7):643-7.

14.

Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.

Blau IW, Schmidt-Hieber M, Leschinger N, Göldner H, Knauf W, Hopfenmüller W, Thiel E, Blau O.

Ann Hematol. 2007 Aug;86(8):583-9. Epub 2007 Apr 28.

PMID:
17468869
15.

[Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].

Ma X, Wu DP, Sun AN, Fu ZZ, Tang XW, Wu XJ, Liu YJ, Qiu HY, Miao M, Han Y, Jin ZM, Zhao Y, Xue SL, Wang Y, Chen SN, He GS, Zhou HX, Chang HR.

Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):73-6. Chinese.

PMID:
19563014
16.

Cytopenia and hematopoietic recovery after low intensity conditioning transplants.

Kostova G, Heim D, Passweg J, Buser A, Tichelli A, Gratwohl A.

Croat Med J. 2004 Aug;45(4):445-50.

17.

Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.

Kono N, Ohashi K, Sasaki E, Okoshi Y, Mizuchi D, Mori S, Akiyama H, Karasawa K, Kaku H, Okamoto R, Maeda Y, Sasaki T, Okuyama Y, Hiruma K, Sakamaki H.

Int J Hematol. 2001 Jan;73(1):122-5.

PMID:
11372748
18.

Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MR, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1313-23. Epub 2007 Sep 7.

19.

Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.

van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman R.

Bone Marrow Transplant. 2000 Aug;26(4):445-9.

20.

Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.

Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K, Lohse P, Sykora KW.

Bone Marrow Transplant. 2007 Feb;39(3):143-7. Epub 2007 Jan 8.

PMID:
17211437

Supplemental Content

Support Center